Secondary allosteric M3 receptor binding for tiotropium: implications for bronchoprotection and functional interactions with LABAs

R. Gosens (Groningen, Netherlands)

Source: International Congress 2017 – Novel studies on bronchodilators and cough
Session: Novel studies on bronchodilators and cough
Session type: Oral Presentation
Number: 4408
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Gosens (Groningen, Netherlands). Secondary allosteric M3 receptor binding for tiotropium: implications for bronchoprotection and functional interactions with LABAs. 4408

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A potential role for dissociation rate from the M3 muscarinic receptor in the onset of action of NVA237 and tiotropium
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010

Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016


Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists
Source: Eur Respir Monogr 2020; 88: 238-250
Year: 2020


Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016



Crosstalk between long acting b2-adrenergic receptor agonists and tiotropium: Crosstalk of b2-adrenergic and muscarinic receptors
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010

Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


The efficacy and safety of long-acting muscarinic antagonist treatment for COPD
Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma
Year: 2019


Slow dissociation kinetics of LAMAs contribute to the functional interactions with LABAs
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review
Source: Annual Congress 2011 - Asthma management and response
Year: 2011


A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA)
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015


Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017

In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA)
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

An oral selective M3 cholinergic receptor antagonist in COPD
Source: Eur Respir J 2006 Oct 01;28(4):772-780
Year: 2006



Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond
Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020
Year: 2020



Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Anti-inflammatory and immunomodulatory potential of Cys LT1 receptor antagonists (LTRA) in steroid dependent persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 136s
Year: 2005

Lack of glucocorticoid receptor activation by formoterol and salmeterol in human bronchial epithelial cells
Source: Eur Respir J 2003; 22: Suppl. 45, 454s
Year: 2003

Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010